Slide 1: Orion Financial Review for 2013
Orion Financial Review for 2013 4 February 2014 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements disclaimer
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Orion's net sales over EUR 1 billion
Orion’s net sales over EUR 1 billion • Net sales exceeded EUR 1 billion • Operating profit slightly lower than in previous year as anticipated • Marketing authorisation application for Easyhaler® combined budesonide-formoterol formulation in Europe • Novartis submitted marketing authorisation applic
Slide 4: Net sales and operating profit
Net sales and operating profit Group key figures 2013 2012* Change % Net sales, EUR million 1,007 980 +3% Operating profit, EUR million 268 278 -4% Basic earnings per share, EUR 1.46 1.47 - Cash flow per share before financial items, EUR 1.02 1.23 -17% • Net sales up by 3% and exceeded EUR 1 billion
Slide 5: Breakdown of net sales
Breakdown of net sales By business division By market area Proprietary Products Specialty Products Finland Scandinavia Other Europe North America Other countries Animal Health Fermion Contract manufacturing & other Orion Diagnostica 13% 6% 4% 27% 6% 39% 14% 7% 13% 38% 33% 5 4 February 2014 Orion Fin
Slide 6: Business Reviews
Business Reviews
Slide 7: Pharmaceuticals business
Pharmaceuticals business Key figures for Pharmaceuticals business 2013 2012* Change % Net sales of Pharmaceuticals, EUR million 953 929 +3% Proprietary Products 390 404 -3% Specialty Products 385 367 +5% Animal Health 71 69 +2% Fermion 64 48 +31% Contract manufacturing and other 43 41 +7% Pharmaceut
Slide 8: Best-selling pharmaceuticals
Best-selling pharmaceuticals Business Orion’s best-selling pharmaceuticals, EUR million Division 2013 2012 Change % 1. Stalevo®, Comtess® and Comtan® (Parkinson’s PP disease) 207 250 -17% 2. Precedex® (intensive care sedative) PP 59 45 +30% 3. Simdax® (acute decompensated heart failure) PP 46 44 +6%
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in 2013 companies in 2013 EUR million • Wholesale EUR 2,067 million (+2%) 250 233 Orion in Finnish human 200 pharmaceuticals market • Sales growth 6% 150 126 130 130 • Orion clear market leader
Slide 10: Review of Parkinson's drugs markets
Review of Parkinson’s drugs markets Overall markets for Parkinson’s drugs Market shares of Orion’s MAT9 MAT9 October 2012 ─ September 2013 branded Parkinson’s drugs 2013 2012 • United States 3) USD 791 million (+5%) Finland 2) 23% 25% • Five largest European markets 1) 3) Sweden 2) 15% 14% EUR 979 m
Slide 11: Precedex and dexdor growing strongly
Precedex® and dexdor® growing strongly Breakdown of Precedex Markets for Precedex® intensive care USD million markets sedative October 2012 ─ September 2013 300 • Total USD 323 million (+30%) 250 200 • United States USD 264 million (+36%) 150 Sales of dexdor® intensive care sedative 100 October 2012
Slide 12: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Clinical phases Project Indication Registration I II III Easyhaler® budesonide-formoterol Asthma, COPD Stalevo® for Japanese markets 1) Parkinson’s disease Easyhaler® salmeterol-fluticasone Asthma, COPD ORM-12741 (alpha-2c adrenoceptor IIa Alzheimer’s
Slide 13: Diagnostics business
Diagnostics business Key figures for Diagnostics business 2013 2012* Change % Net sales, EUR million 57 54 +5% Operating profit, EUR million 4.6 2.3 +97% • Good growth in sales and measures to improve cost efficiency increased profit. Profit includes EUR 1.4 million of expenses related to contractio
Slide 14: Outlook for 2014
Outlook for 2014 • Net sales will be at similar level to 2013 (net sales in 2013 were EUR 1,007 million) • Operating profit will be slightly lower than in 2013 (operating profit in 2013 was EUR 268 million) • Group’s capital expenditure will be about EUR 60 million excluding substantial corporate or
Slide 15: Orion Calendar 2014
Orion Calendar 2014 • Deadline for registering for AGM 20 March 2014 at 10:00 • Annual General Meeting 25 March 2014 at 14:00 • Record date for dividend distribution 28 March 2014 • Dividend payment date 4 April 2014 • Interim Report January─March 2014 29 April 2014 • Interim Report January─June 201
Slide 16: Orion - Building well-being
GRION Building well-being
Slide 17: Orion's financial objectives
Orion’s financial objectives Orion’s financial objectives are: • Ensuring financial stability • Profitable growth The objectives are achieved through: • Increasing net sales. Achievement of this objective requires continuous investment in development of the product portfolio. • Maintaining profitabi
Slide 18: Key figures by quarter
Key figures by quarter EUR million Net sales EUR million Operating profit 1200 300 283 278 268 980 1,007 254 1000 918 250 60 59 850 207 53 66 772 254 273 800 236 Q4 200 65 Q4 215 44 76 193 71 67 600 246 237 Q3 150 Q3 211 56 213 65 192 Q2 65 Q2 400 100 60 61 227 233 248 50 196 207 Q1 Q1 200 50 93 71
Slide 19: Key figures for 2009-2013
Key figures for 2009─2013 Orion’s key figures 2009 2010 2011 2012* 2013 Change % Net sales, EUR million 771.5 849.9 917.9 980.4 1,006.9 +2.7% Operating profit, EUR million 207.0 254.2 282.9 278.3 267.7 -3.8% Profit before taxes, EUR million 203.7 252.6 282.0 276.6 264.0 -4.6% R&D expenses, EUR milli
Slide 20: Income Statement 2009-2013
Income Statement 2009─2013 Formation of profits, EUR million 2009 2010 2011 2012* 2013 Change % Net sales 771.5 849.9 917.9 980.4 1,006.9 +2.7% Cost of goods sold -265.2 -283.2 -305.1 -350.8 -393.5 +12.2% Gross profit 506.3 566.8 612.8 629.6 613.4 -2.6% Other operating income and expenses 6.0 1.2 3.
Slide 21: Product protection situation of key products
Product protection situation of key products Key patents or data protection expire Molecule Product Indication Europe USA Japan Stalevo®, November 2012 January Entacapone Parkinson’s disease October 2013 Comtess® and Comtan® October 2013 1) 2015 2) Acute Levosimendan Simdax® decompensated September
Slide 22: Dividend distribution policy
Dividend distribution policy Dividend distribution history Dividend distribution policy EUR 1.40 140% Orion’s dividend distribution takes into 1.20 120% account distributable funds and capital 1.00 100% expenditure and other financial 0.80 80% requirements in medium and long term to achieve the fina
Slide 23: Slide 23